Purple Biotech (PPBT) is advancing into a Phase 2 study with NT219 in patients with recurrent/metastatic squamous cell carcinoma of the head ...

NT219, a novel agent designed to overcome tumor resistance to drug therapy, will be evaluated in combination with the standard-of-care head and ...

CINCINNATI (WKRC) — Mysta Bee, a young artist battling throat cancer, is advancing to the next phase of his treatment plan. Diagnosed after a mass on his neck left him unable to breathe, Mysta Bee, ...

Using a new technology and computational method, researchers have uncovered a biomarker capable of accurately predicting outcomes in meningioma brain tumors and breast cancers.